Skip to main content
. Author manuscript; available in PMC: 2018 Mar 27.
Published in final edited form as: Sci Transl Med. 2017 Sep 27;9(409):eaan0241. doi: 10.1126/scitranslmed.aan0241

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520.

Fig. 3

Following pre-study evaluation, nine chimpanzees began NUC dosing for a lead-in period of 8–24 weeks. Q4W dosing with ARC-520 began on Day 1. (A) HBsAg levels in serum. The mean log10 change in HBsAg is shown for the 8 weeks preceding the first dose of ARC-520 and during ARC-520 treatment of four HBeAg positive (●), four HBeAg negative (□), and in the HBeAg transitional chimpanzee (▲). (B, C) Liver mRNA from biopsies of HBeAg positive (A2A004, A3A006 and A4A014) and HBeAg negative (88A010, 95A008 and 95A010) chimpanzees was evaluated for HBV gene expression by RT-qPCR with probe sets in core to measure the levels of precore mRNA/pgRNA and in X to measure total HBV mRNA. (B) Mean total HBV mRNA levels were compared between HBeAg positive and negative chimpanzees pre-study, after the NUC lead-in (Day 1), and one week after the second ARC-520 injection (Day 36). (C) The numbers of total HBV transcripts and precore/pgRNA transcripts on Day 1 are compared for the HBeAg positive and negative chimpanzees. Error bars show SEM.